Family Heart Foundation Study Shows Increased Rate of Cardiovascular Events Among Individuals With High Lipoprotein(a)
So important
Related Articles
Pitch deck: Why Google believes its latest AI Max product is a game changer for search campaigns
AI Max, which launched May and rolls out this summer, aims to provide advertisers with a “one-click feature suite” for search campaigns.
QOL Data Could Help Support Switch to Camizestrant in HR+ Breast Cancer After Emergence of ESR1 Mutation
Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.
How this medical student-led clinic tackled measles, TB protocols
At JayDoc, the University of Kansas Medical School’s free clinic, medical student leaders are helping to shape public health readiness.
In Landmark Shift, NIH Announces No More Exclusive Funding for Animal Experiments
Washington, D.C. – In a historic move, the U.S. National Institutes of Health (NIH) announced today that it will no longer seek research proposals exclusively…
NIH Plans to Limit Publisher Fees for Agency-Funded Research
The NIH is planning to limit how much publishers can charge NIH-supported scientists to make their research findings publicly available.
Women Are 2X More Likely To Deal With This Common Issue Than Men
A study finds that women are more than twice as likely as men to report feeling bloated.
China’s massive coastal restoration project could backfire
Study finds that efforts to replace an invasive weed could spike greenhouse gas emissions in the region
Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses
Co-option of primate-specific retroelements creates an alternative IL-13Rα1 subunit that tunes type 2 immune responses.
How the largest digital camera ever made is revolutionizing our view of space
This new telescope lets you hold 10 million galaxies in your hand.
TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation
Key PointsPatients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity.Transplant
